POTENTIAL EFFECTS OF KETOGENIC DIETS, A NARRATIVE REVIEW
Background: Ketogenic diets have a long history of therapeutic use and have recently attracted significant attention due to their promising effects on a variety of disorders. However, no definitive links have been identified. This review aims to highlight the possible impacts of ketogenic diets as well as the mechanisms involved in metabolic processes and related non-communicable metabolic diseases. Methods: For our analysis, a bibliographic review of articles about ketogenic diets and their therapeutic effect on chronic pathologies was carried out, retrieved from the scientific literature. Results and discussion: These studies found both positive and negative outcomes for the effects and implications of ketogenic diets on metabolism. Significant differences in metabolic markers such as weight, glycemia, serum lipids and lipoproteins, anthropometric measures, and hormones such as insulin, leptin, and adiponectin have been reported. In addition to changes in the microbiome that have modest to moderate concurrent effects, changes in metabolism indicate the significance of dietary changes in treating and preventing chronic non-communicable diseases. Conclusions: In this review, we present the available scientific evidence on the effects of the ketogenic diet, and thus ketone bodies, on metabolism and related chronic diseases.
Read ArticleTREATMENTS FOR ACUTE LYMPHOBLASTIC LEUKEMIA: A COMPARISON BETWEEN TISAGENLECLEUCEL AND CLOFARABINE
Background: Acute lymphoblastic leukemia (ALL) is a heterogeneous hematological malignancy predominantly affecting individuals under 20 years of age. Traditional chemotherapy, such as clofarabine, has shown efficacy; however, novel immunotherapeutic strategies like tisagenlecleucel (Kymriah®) have significantly altered the treatment paradigm. Aim: This study aimed to perform a comparative analysis of tisagenlecleucel, a CAR-T cell therapy, and clofarabine, a second-generation purine nucleoside analog, evaluating their mechanisms of action, therapeutic benefits, limitations, and clinical applicability across diverse patient populations. Methods: A systematic comparative evaluation was conducted, encompassing pharmacological characteristics, mechanisms of action, treatment protocols, efficacy, safety profiles, and clinical indications of both agents. The analysis considered pharmacokinetic and pharmacodynamic data and included patient demographic variables. Results: Tisagenlecleucel demonstrated high efficacy in refractory B-cell ALL, with durable responses and a blood half-life of 128 days, but with notable immune-related adverse effects such as cytokine release syndrome. Clofarabine, effective across a broader patient population, acts via multiple antitumor mechanisms but carries significant toxicity risks, including infection and sepsis. Discussion: The therapies present distinct clinical profiles: tisagenlecleucel offers targeted immunotherapy with high specificity but requires specialized infrastructure and management of immune toxicities. Clofarabine is more widely accessible and applicable, but is associated with conventional chemotherapy-related side effects. Treatment accessibility and cost differ markedly between the two. Conclusions: Therapy selection should be personalized based on patient-specific factors and institutional resources. Tisagenlecleucel is ideal for pediatric and young adult patients with relapsed/refractory B-cell ALL in CAR-T-capable centers, while clofarabine remains a viable option for broader ALL populations, particularly when genetic therapies are not feasible. Further research is needed to optimize therapeutic strategies and improve access to advanced treatments.
Read ArticleANTIBIOTIC SUSCEPTIBILITY OF ESCHERICHIA COLI ISOLATE FROM URINARY TRACT INFECTION OF THALASSEMIC PATIENTS IN THI-QAR PROVINCE
Escherichia coli (E. coli) is the most common type of pathogen that causes Urinary tract infection disease. It can be presented as a pathogenic or non-pathogenic strain and found not only in the animal but also in the human intestine. This bacterium can cause opportunistic infection when the human host comprised of thalassemia patients or changes the healthy hemostatic flora. This study aimed to analyze the presence of bacteria in thalassemia patients with urinary tract infection. A total of 303 samples were collected during the period from August 2019 to January 2020 from thalassemia patients who suffered from urinary tract infection. The results showed that there were 6.9% of patients infected with E. coli, 2.6% of patients were infected with S. aureus, 0.7% with both Proteus and Klebsiella, while 89.1% of patients had a negative sample for bacteria. Also, the incidence of urinary tract infections in females is higher than in males. Besides, its occurrence in rural areas is higher than in city residents. Moreover, among 16 antibiotics tested to sensitize bacteria to antibiotics, Imipenem showed 100% efficacy on all isolated bacteria. In contrast, Netilmicin showed 80.1% efficacy, Gentamycin 80.1%, and Amikacin 76.2%. Ampicillin, Aztreonam, Amoxicillin-Clavulanic Acid, Tetracycline, and Ticarcillin-Clavulanic Acid, did not show any effectiveness toward the bacteria while other antibiotics showed different activities. Furthermore, the isolated microbes from thalassemia patients were the highest resistance to antibiotics in comparison with other studies, and this antibiotic-resistant may be due to the weakening of the patient's immune status and frequent blood taking and the antibodies it contains.
Read Article